Candel Therapeutics, Inc. — Director's Dealing 2021

Jul 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-27

Reporting Person: Manning Paul B (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-27	Common Stock	P	36000	$7.3565	Acquired	36000	Direct
2021-07-29	Common Stock	P	20000	$7.2972	Acquired	56000	Direct

Footnotes

F1: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.31 to $7.40. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

F2: Shares held jointly with spouse.

F3: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.855 to $7.80. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.